Chen Pengyu, Quan Zhen, Song Xueyu, Gao Zhaojia, Yuan Kai
Division of Thoracic Surgery, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China.
School of Medicine, Dalian Medical University, Dalian, China.
Front Oncol. 2022 Oct 10;12:1005962. doi: 10.3389/fonc.2022.1005962. eCollection 2022.
Approximately 80% of lung cancers are non-small cell lung cancers (NSCLC). Lung adenocarcinoma (LUAD) is the main subtype of NSCLC. The incidence and mortality of lung cancer are also increasing yearly. Myogenic differentiation family inhibitor () as a transcription factor, its role in lung cancer has not yet been clarified.
LUAD data were downloaded from The Cancer Genome Atlas (TCGA) database and Gene Expression Omnibus (GEO), analyzed and plotted using the R language. Associations between Clinical information and expression were assessed using logistic regression analyses to explore the effects of on LUAD. Two sets of tissue microarrays (TMAs) further confirmed the overexpression of in LUAD and its impact on prognosis. In addition, we examined the correlation between and immune infiltration. To investigate the effect of on the biological behavior of LUAD tumor cells by GSEA and GO/KEGG analysis. The survival status and somatic mutational characteristics of patients according to levels were depicted and analyzed.
Expression of high in LUAD tissues analyzing TCGA dataset (0.001). Kaplan-Meier survival analysis indicated a poor prognosis for those patients with LUAD who had upregulated expression levels (0.001). This was also verified by two groups of TMAs (=0.024). Using logistic statistics analysis, was identified as an independent predictive factor and was associated with poor prognosis in LUAD (0.001, =0.021). Assessment of clinical characteristics, tumor mutation burden (TMB), and tumor microenvironment (TME) between high- and low-expression score groups showed lower TMB, richer immune cell infiltration, and better prognosis in the low-risk group.
This study showed that was overexpressed in LUAD and was significantly associated with poor prognosis, indicating that may be used as a potential novel biomarker for the diagnosis and prognosis of LUAD. is associated with immune infiltration of LUAD and it is reasonable to speculate that it plays an important role in tumor proliferation and spread. In view of the significant differences in expression between different biological activities, LUAD patients with overexpression may obtain more precise treatment strategies in the clinic.
约80%的肺癌为非小细胞肺癌(NSCLC)。肺腺癌(LUAD)是NSCLC的主要亚型。肺癌的发病率和死亡率也在逐年上升。肌源性分化家族抑制剂()作为一种转录因子,其在肺癌中的作用尚未阐明。
从癌症基因组图谱(TCGA)数据库和基因表达综合数据库(GEO)下载LUAD数据,使用R语言进行分析和绘图。采用逻辑回归分析评估临床信息与表达之间的关联,以探讨对LUAD的影响。两组组织芯片(TMA)进一步证实了在LUAD中的过表达及其对预后的影响。此外,我们检测了与免疫浸润之间的相关性。通过基因集富集分析(GSEA)和基因本体论/京都基因与基因组百科全书(GO/KEGG)分析来研究对LUAD肿瘤细胞生物学行为的影响。根据水平描绘并分析患者的生存状态和体细胞突变特征。
分析TCGA数据集发现,LUAD组织中高表达(0.001)。Kaplan-Meier生存分析表明,LUAD患者中表达水平上调者预后较差(0.001)。两组TMA也证实了这一点(=0.024)。通过逻辑统计分析,被确定为独立预测因子,且与LUAD的不良预后相关(0.001,=0.021)。对高表达评分组和低表达评分组之间的临床特征、肿瘤突变负荷(TMB)和肿瘤微环境(TME)进行评估,结果显示低风险组的TMB较低、免疫细胞浸润更丰富且预后更好。
本研究表明在LUAD中过表达,且与不良预后显著相关,这表明可能用作LUAD诊断和预后的潜在新型生物标志物。与LUAD的免疫浸润相关,推测其在肿瘤增殖和扩散中起重要作用是合理的。鉴于不同生物学活性之间表达存在显著差异,过表达的LUAD患者在临床上可能获得更精准的治疗策略。